ADA
EstablishedADA is a fluid-based enzyme test used mainly to diagnose tuberculous pleural effusion.
ADA is an enzyme measured in fluid drawn from around the lungs to help diagnose tuberculosis. A high level is a strong clue for TB, especially in regions where TB is common, but as TB becomes less common, doctors need higher cutoffs to avoid mistaking cancer-related fluid buildup for TB.
Adenosine deaminase (ADA) is an enzyme involved in purine metabolism that is released by activated T-lymphocytes. Elevated levels in body fluids reflect a cell-mediated immune response, most classically in tuberculous infection.
Pleural fluid ADA is a well-established, low-cost marker for diagnosing tuberculous pleural effusion (TPE), especially valuable in high-burden regions where invasive pleural biopsy carries real risk. It is also elevated in some malignant and other lymphocyte-rich effusions, requiring careful interpretation.
Measured in pleural (or other body cavity) fluid; the traditional cutoff is ≥40 U/L, though optimal thresholds vary by population and TB prevalence — a 2026 Malaysian study proposed ≥36 U/L for better sensitivity in that setting, sometimes combined with an LDH/ADA ratio for improved specificity.
In low-to-medium TB prevalence settings (e.g., South Korea), the conventional 40 U/L cutoff performs poorly because malignant effusions increasingly populate the 40–70 U/L "gray zone," prompting recommendations for raised, locally-validated cutoffs (e.g., ≥70 U/L) to avoid false-positive TB diagnoses in cancer patients.
A well-validated, inexpensive marker for TB pleuritis, with population-dependent optimal cutoffs.
- Shien, et al. (2026). Diagnostic utility of pleural fluid adenosine deaminase in tuberculous pleural effusion (ADATPE study). Journal of Thoracic Disease.
- Lee, J., et al. (2022). Investigating the appropriate ADA cutoff value for TPE diagnosis in a country with decreasing TB burden. Scientific Reports.